

Matilde Todaro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1766597/publications.pdf>

Version: 2024-02-01

119
papers

17,564
citations

36303

51
h-index

22832

112
g-index

124
all docs

124
docs citations

124
times ranked

21857
citing authors

#	ARTICLE	IF	CITATIONS
1	PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells. <i>Gut</i> , 2022, 71, 119-128.	12.1	46
2	Dual Inhibition of Myc Transcription and PI3K Activity Effectively Targets Colorectal Cancer Stem Cells. <i>Cancers</i> , 2022, 14, 673.	3.7	4
3	Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51. <i>Oncogene</i> , 2022, 41, 2196-2209.	5.9	8
4	Targeting of the Peritumoral Adipose Tissue Microenvironment as an Innovative Antitumor Therapeutic Strategy. <i>Biomolecules</i> , 2022, 12, 702.	4.0	3
5	Magnetic Nanoparticle-Based Hyperthermia Mediates Drug Delivery and Impairs the Tumorigenic Capacity of Quiescent Colorectal Cancer Stem Cells. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 15959-15972.	8.0	35
6	The C-X-C Motif Chemokine Ligand 1 Sustains Breast Cancer Stem Cell Self-Renewal and Promotes Tumor Progression and Immune Escape Programs. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 689286.	3.7	22
7	CHK1 inhibitor sensitizes resistant colorectal cancer stem cells to nortopsentin. <i>IScience</i> , 2021, 24, 102664.	4.1	31
8	Messing Up the Cancer Stem Cell Chemoresistance Mechanisms Supported by Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 702642.	2.8	21
9	Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery. <i>Nature Communications</i> , 2021, 12, 5006.	12.8	38
10	Nobiletin and Xanthohumol Sensitize Colorectal Cancer Stem Cells to Standard Chemotherapy. <i>Cancers</i> , 2021, 13, 3927.	3.7	20
11	Interleukin-30 feeds breast cancer stem cells via CXCL10 and IL23 autocrine loops and shapes immune contexture and host outcome. , 2021, 9, e002966.		13
12	Targeting Phosphatases and Kinases: How to Checkmate Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 690306.	3.7	21
13	Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant. <i>Oncogene</i> , 2020, 39, 987-1003.	5.9	24
14	ROS and Lipid Droplet accumulation induced by high glucose exposure in healthy colon and Colorectal Cancer Stem Cells. <i>Genes and Diseases</i> , 2020, 7, 620-635.	3.4	26
15	Cancer Stem Cells in Thyroid Tumors: From the Origin to Metastasis. <i>Frontiers in Endocrinology</i> , 2020, 11, 566.	3.5	22
16	Metabolic Escape Routes of Cancer Stem Cells and Therapeutic Opportunities. <i>Cancers</i> , 2020, 12, 1436.	3.7	15
17	Cancer Stem Cells: From Birth to Death. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 1-30.	0.1	1
18	Meeting the Challenge of Targeting Cancer Stem Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 16.	3.7	109

#	ARTICLE	IF	CITATIONS
19	Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway. <i>Cancer Immunology Research</i> , 2019, 7, 841-852.	3.4	47
20	Capturing colorectal cancer inter-tumor heterogeneity in patient-derived xenograft (PDX) models. <i>International Journal of Cancer</i> , 2019, 144, 366-371.	5.1	32
21	MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state. <i>Nature Communications</i> , 2018, 9, 1024.	12.8	114
22	Microenvironment in neuroblastoma: isolation and characterization of tumor-derived mesenchymal stromal cells. <i>BMC Cancer</i> , 2018, 18, 1176.	2.6	51
23	MiR-205-5p inhibition by locked nucleic acids impairs metastatic potential of breast cancer cells. <i>Cell Death and Disease</i> , 2018, 9, 821.	6.3	32
24	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. <i>Scientific Reports</i> , 2017, 7, 43013.	3.3	44
25	IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition. <i>Cancer Research</i> , 2017, 77, 3268-3279.	0.9	49
26	Innovative Therapeutic Strategies Targeting Colorectal Cancer Stem Cells. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 91-100.	0.5	1
27	Noncanonical GLI1 signaling promotes stemness features and in vivo growth in lung adenocarcinoma. <i>Oncogene</i> , 2017, 36, 4641-4652.	5.9	86
28	Squamous Cell Tumors Recruit $\gamma\delta$ T Cells Producing either IL17 or IFN γ Depending on the Tumor Stage. <i>Cancer Immunology Research</i> , 2017, 5, 397-407.	3.4	59
29	Distinctive features of tumor-infiltrating $\gamma\delta$ T lymphocytes in human colorectal cancer. <i>Oncolmmunology</i> , 2017, 6, e1347742.	4.6	119
30	Role of Type I and II Interferons in Colorectal Cancer and Melanoma. <i>Frontiers in Immunology</i> , 2017, 8, 878.	4.8	60
31	Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. <i>Oncotarget</i> , 2017, 8, 108463-108479.	1.8	8
32	MiR-24 induces chemotherapy resistance and hypoxic advantage in breast cancer. <i>Oncotarget</i> , 2017, 8, 19507-19521.	1.8	63
33	Targeting DNA double strand break repair with hyperthermia and DNA-PKcs inhibition to enhance the effect of radiation treatment. <i>Oncotarget</i> , 2016, 7, 65504-65513.	1.8	38
34	MiR-221 promotes stemness of breast cancer cells by targeting DNMT3b. <i>Oncotarget</i> , 2016, 7, 580-592.	1.8	84
35	Apoptosis induced by a HIPK2 full-length-specific siRNA is due to off-target effects rather than prevalence of HIPK2- β isoform. <i>Oncotarget</i> , 2016, 7, 1675-1686.	1.8	5
36	Activated Thyroid Hormone Promotes Differentiation and Chemotherapeutic Sensitization of Colorectal Cancer Stem Cells by Regulating Wnt and BMP4 Signaling. <i>Cancer Research</i> , 2016, 76, 1237-1244.	0.9	72

#	ARTICLE	IF	CITATIONS
37	Normal vs cancer thyroid stem cells: the road to transformation. <i>Oncogene</i> , 2016, 35, 805-815.	5.9	22
38	p63 role in breast cancer. <i>Aging</i> , 2016, 8, 2256-2257.	3.1	10
39	miR-Np63 drives metastasis in breast cancer cells via PI3K/CD44v6 axis. <i>Oncotarget</i> , 2016, 7, 54157-54173.	1.8	25
40	Abstract 2484: Non-canonical Hedgehog/Gli1 signaling drives lung adenocarcinoma stem cells survival and its targeting inhibits CSC-derived tumors. , 2016, , .		0
41	Abstract 3311: Autocrine and paracrine IL-4 maintains breast cancer stem cells traits via RAS/MAPK/DUSP pathway. , 2016, , .		0
42	A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology. <i>PLoS ONE</i> , 2015, 10, e0125697.	2.5	14
43	Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study. <i>PLoS ONE</i> , 2015, 10, e0125037.	2.5	9
44	miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance. <i>Cell Death and Disease</i> , 2015, 6, e1823-e1823.	6.3	74
45	Dynamic regulation of the cancer stem cell compartment by Cripto-1 in colorectal cancer. <i>Cell Death and Differentiation</i> , 2015, 22, 1700-1713.	11.2	50
46	Lipid Droplets: A New Player in Colorectal Cancer Stem Cells Unveiled by Spectroscopic Imaging. <i>Stem Cells</i> , 2015, 33, 35-44.	3.2	185
47	TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. <i>Oncogene</i> , 2015, 34, 681-690.	5.9	287
48	By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy. <i>Oncotarget</i> , 2015, 6, 2315-2330.	1.8	43
49	Targeting Cancer Stem Cells and the Tumor Microenvironment. , 2015, , 445-476.		0
50	Abstract LB-143: DNp63 governs metastatic outgrowth of breast cancer stem cells. , 2015, , .		0
51	Estrogens and Stem Cells in Thyroid Cancer. <i>Frontiers in Endocrinology</i> , 2014, 5, 124.	3.5	18
52	CD8 ⁺ T cells as a potential tool in colon cancer immunotherapy. <i>Immunotherapy</i> , 2014, 6, 989-999.	2.0	17
53	Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment. <i>Cell Death and Disease</i> , 2014, 5, e1336-e1336.	6.3	219
54	Colorectal Cancer Stem Cells: From the Crypt to the Clinic. <i>Cell Stem Cell</i> , 2014, 15, 692-705.	11.1	340

#	ARTICLE	IF	CITATIONS
55	CD44v6 Is a Marker of Constitutive and Reprogrammed Cancer Stem Cells Driving Colon Cancer Metastasis. <i>Cell Stem Cell</i> , 2014, 14, 342-356.	11.1	617
56	Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer. <i>Cell Death and Differentiation</i> , 2014, 21, 1877-1888.	11.2	90
57	Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell-Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4. <i>Journal of Immunology</i> , 2014, 192, 523-532.	0.8	97
58	p63 Isoforms Regulate Metabolism of Cancer Stem Cells. <i>Journal of Proteome Research</i> , 2014, 13, 2120-2136.	3.7	25
59	Abstract 3897: Sam68 sustains self-renewal and invasiveness of breast cancer initiating cells. , 2014, , .		0
60	Tumor and its microenvironment: A synergistic interplay. <i>Seminars in Cancer Biology</i> , 2013, 23, 522-532.	9.6	344
61	Erythropoietin Activates Cell Survival Pathways in Breast Cancer Stem-like Cells to Protect Them from Chemotherapy. <i>Cancer Research</i> , 2013, 73, 6393-6400.	0.9	37
62	Mechanisms underlying lineage commitment and plasticity of human $\hat{\gamma}$ T cells. <i>Cellular and Molecular Immunology</i> , 2013, 10, 30-34.	10.5	66
63	Human NK Cells Selective Targeting of Colon Cancer-Initiating Cells: A Role for Natural Cytotoxicity Receptors and MHC Class I Molecules. <i>Journal of Immunology</i> , 2013, 190, 2381-2390.	0.8	224
64	Combining conventional chemotherapy and $\hat{\gamma}$ T cell-based immunotherapy to target cancer-initiating cells. <i>Onc Immunology</i> , 2013, 2, e25821.	4.6	37
65	Distribution, function and predictive value of tumor-infiltrating $\hat{\gamma}$ T lymphocytes. <i>Onc Immunology</i> , 2013, 2, e23434.	4.6	6
66	Chemotherapy Sensitizes Colon Cancer Initiating Cells to $\hat{\gamma}$ T Cell-Mediated Cytotoxicity. <i>PLoS ONE</i> , 2013, 8, e65145.	2.5	41
67	CD133 as a target for colon cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 259-267.	3.4	30
68	Proliferation State and Polo-Like Kinase1 Dependence of Tumorigenic Colon Cancer Cells. <i>Stem Cells</i> , 2012, 30, 1819-1830.	3.2	53
69	IL-21 Regulates the Differentiation of a Human $\hat{\gamma}$ T Cell Subset Equipped with B Cell Helper Activity. <i>PLoS ONE</i> , 2012, 7, e41940.	2.5	54
70	Characterization of Human $\hat{\gamma}$ T Lymphocytes Infiltrating Primary Malignant Melanomas. <i>PLoS ONE</i> , 2012, 7, e49878.	2.5	137
71	Human Thyroid Cancer Stem Cells. , 2012, , 137-143.		0
72	Detection of Cancer Stem Cells Using AC133 Antibody. , 2012, , 37-43.		0

#	ARTICLE	IF	CITATIONS
73	Bone Morphogenetic Protein 4 Induces Differentiation of Colorectal Cancer Stem Cells and Increases Their Response to Chemotherapy in Mice. <i>Gastroenterology</i> , 2011, 140, 297-309.e6.	1.3	202
74	Differentiation, phenotype, and function of interleukin-17-producing human $\text{V}\alpha 9\text{V}\beta 2$ T cells. <i>Blood</i> , 2011, 118, 129-138.	1.4	262
75	Immunotherapy targeting colon cancer stem cells. <i>Immunotherapy</i> , 2011, 3, 97-106.	2.0	19
76	Colon Cancer Stem Cells: Bench-to-Bedside—New Therapeutical Approaches in Clinical Oncology for Disease Breakdown. <i>Cancers</i> , 2011, 3, 1957-1974.	3.7	9
77	Colorectal Cancer Stem Cells and Cell Death. <i>Cancers</i> , 2011, 3, 1929-1946.	3.7	15
78	Prevention of Chemotherapy-Induced Anemia and Thrombocytopenia by Constant Administration of Stem Cell Factor. <i>Clinical Cancer Research</i> , 2011, 17, 6185-6191.	7.0	24
79	Survivin is regulated by interleukin-4 in colon cancer stem cells. <i>Journal of Cellular Physiology</i> , 2010, 225, 555-561.	4.1	77
80	<i>In vivo</i> manipulation of $\text{V}\alpha 9\text{V}\beta 2$ T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. <i>Clinical and Experimental Immunology</i> , 2010, 161, 290-297.	2.6	266
81	Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. <i>Nature</i> , 2010, 468, 824-828.	27.8	1,235
82	Aurora-A Is Essential for the Tumorigenic Capacity and Chemoresistance of Colorectal Cancer Stem Cells. <i>Cancer Research</i> , 2010, 70, 4655-4665.	0.9	138
83	Tumorigenic and Metastatic Activity of Human Thyroid Cancer Stem Cells. <i>Cancer Research</i> , 2010, 70, 8874-8885.	0.9	197
84	$\text{V}\alpha 9\text{V}\beta 2$ T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells. <i>Journal of Immunology</i> , 2010, 184, 3260-3268.	0.8	132
85	Colon Cancer Stem Cells: Promise of Targeted Therapy. <i>Gastroenterology</i> , 2010, 138, 2151-2162.	1.3	411
86	Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. <i>Nature Cell Biology</i> , 2010, 12, 468-476.	10.3	1,623
87	Suppressor of Cytokine Signaling 3 Sensitizes Anaplastic Thyroid Cancer to Standard Chemotherapy. <i>Cancer Research</i> , 2009, 69, 6141-6148.	0.9	32
88	Efficient Killing of Human Colon Cancer Stem Cells by $\text{V}\alpha 9\text{V}\beta 2$ T Lymphocytes. <i>Journal of Immunology</i> , 2009, 182, 7287-7296.	0.8	260
89	Therapeutic implications of cancer initiating cells. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 1005-1016.	3.1	52
90	Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. <i>Cell Death and Differentiation</i> , 2008, 15, 762-772.	11.2	191

#	ARTICLE	IF	CITATIONS
91	Isolation and Culture of Colon Cancer Stem Cells. <i>Methods in Cell Biology</i> , 2008, 86, 311-324.	1.1	83
92	Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 13427-13432.	7.1	654
93	Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme. <i>Clinical Cancer Research</i> , 2008, 14, 8205-8212.	7.0	327
94	Crucial Role of Interleukin-4 in the Survival of Colon Cancer Stem Cells. <i>Cancer Research</i> , 2008, 68, 4022-4025.	0.9	113
95	Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. <i>Cardiovascular Research</i> , 2008, 80, 416-424.	3.8	147
96	IL-4-mediated drug resistance in colon cancer stem cells. <i>Cell Cycle</i> , 2008, 7, 309-313.	2.6	125
97	The Antiapoptotic Protein BAG3 Is Expressed in Thyroid Carcinomas and Modulates Apoptosis Mediated by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1159-1163.	3.6	99
98	MUC1 Oncoprotein Promotes Refractoriness to Chemotherapy in Thyroid Cancer Cells. <i>Cancer Research</i> , 2007, 67, 5522-5530.	0.9	33
99	Colon Cancer Stem Cells Dictate Tumor Growth and Resist Cell Death by Production of Interleukin-4. <i>Cell Stem Cell</i> , 2007, 1, 389-402.	11.1	968
100	Identification and expansion of human colon-cancer-initiating cells. <i>Nature</i> , 2007, 445, 111-115.	27.8	3,690
101	Comparative study of T84 and T84SF human colon carcinoma cells: in vitro and in vivo ultrastructural and functional characterization of cell culture and metastasis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 449, 48-61.	2.8	0
102	Autocrine Production of Interleukin-4 and Interleukin-10 Is Required for Survival and Growth of Thyroid Cancer Cells. <i>Cancer Research</i> , 2006, 66, 1491-1499.	0.9	110
103	NF- κ B protects Behçet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. <i>Arthritis and Rheumatism</i> , 2005, 52, 2179-2191.	6.7	59
104	PED Mediates AKT-Dependent Chemoresistance in Human Breast Cancer Cells. <i>Cancer Research</i> , 2005, 65, 6668-6675.	0.9	56
105	Role of Apoptosis in Autoimmunity. <i>Journal of Clinical Immunology</i> , 2004, 24, 1-11.	3.8	25
106	CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells. <i>European Journal of Immunology</i> , 2004, 34, 1930-1940.	2.9	95
107	Islet β -Cell Apoptosis Triggered in Vivo by Interleukin-1 β Is Not Related to the Inducible Nitric Oxide Synthase Pathway: Evidence for Mitochondrial Function Impairment and Lipoperoxidation. <i>Endocrinology</i> , 2003, 144, 4264-4271.	2.8	19
108	Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. <i>Cancer Research</i> , 2003, 63, 6784-90.	0.9	101

#	ARTICLE	IF	CITATIONS
109	Fas-FasL in Hashimoto's thyroiditis. <i>Journal of Clinical Immunology</i> , 2001, 21, 19-23.	3.8	28
110	Involvement of Caspase-3 and GD3 Ganglioside in Ceramide-induced Apoptosis in Farber Disease. <i>Journal of Histochemistry and Cytochemistry</i> , 2000, 48, 57-62.	2.5	34
111	Control of target cell survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins. <i>Nature Immunology</i> , 2000, 1, 483-488.	14.5	139
112	GD3 ganglioside directly targets mitochondria in a bcl-2 controlled fashion. <i>FASEB Journal</i> , 2000, 14, 2047-2054.	0.5	175
113	Potential Involvement of Fas and Its Ligand in the Pathogenesis of Hashimoto's Thyroiditis. <i>Science</i> , 1997, 275, 960-963.	12.6	557
114	Defective Expression of CD95 (FAS/APO-1) Molecule Suggests Apoptosis Impairment of T and B Cells in HLA-B8, DR3-Positive Individuals. <i>Human Immunology</i> , 1997, 55, 39-45.	2.4	21
115	Low bcl-2 expression and increased spontaneous apoptosis in T-lymphocytes from newly-diagnosed IDDM patients. <i>Diabetologia</i> , 1995, 38, 953-958.	6.3	20
116	Defective expression of the apoptosis-inducing CD95 (Fas/APO-1) molecule on T and B cells in IDDM. <i>Diabetologia</i> , 1995, 38, 1449-1454.	6.3	32
117	T-cell activation in HLA-B8,DR3-positive individuals early antigen expression defect in vitro. <i>Human Immunology</i> , 1995, 42, 289-294.	2.4	32
118	Defective T cell receptor/CD3 complex signaling in human type I diabetes. <i>European Journal of Immunology</i> , 1994, 24, 999-1002.	2.9	44
119	Study of T-cell activation in Type I diabetic patients and pre-Type I diabetic subjects by cytometric analysis: Antigen expression defect in vitro. <i>Journal of Clinical Immunology</i> , 1993, 13, 68-78.	3.8	25